Home » Stocks » NEPH

Nephros, Inc. (NEPH)

Stock Price: $7.80 USD -0.19 (-2.38%)
Updated Jan 22, 2021 4:00 PM EST - Market closed
Market Cap 76.75M
Revenue (ttm) 9.39M
Net Income (ttm) -4.15M
Shares Out 9.04M
EPS (ttm) -0.48
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 22
Last Price $7.80
Previous Close $7.99
Change ($) -0.19
Change (%) -2.38%
Day's Open 7.99
Day's Range 7.71 - 8.00
Day's Volume 10,989
52-Week Range 5.58 - 9.45

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 1 week ago

Anticipates $2.3 Million Revenue in Fourth Quarter, $8.5 Million in Full-Year; Quarterly Revenue Grew 9% Sequentially Over Third Quarter; Full Year Revenue Declined 17%

GlobeNewsWire - 2 weeks ago

HDF Assist Device Complete; Special 510(k) to be Filed in Early 2021

GlobeNewsWire - 2 weeks ago

HDF Assist Device Complete; Special 510(k) to be Filed in Early 2021

GlobeNewsWire - 2 months ago

SOUTH ORANGE, NJ, Nov. 09, 2020 (GLOBE NEWSWIRE) -- via NewMediaWire --Nephros, Inc. (Nasdaq: NEPH), a commercial-stage company that develops and sells high performance water purification prod...

GlobeNewsWire - 2 months ago

Finance Veteran Strengthens Management Team; Quarter-over-Quarter Net Revenue up 34%; Year-over-Year down 31%

GlobeNewsWire - 2 months ago

SOUTH ORANGE, NJ, Oct. 29, 2020 (GLOBE NEWSWIRE) -- via NewMediaWire  -- Nephros, Inc. (Nasdaq: NEPH), a commercial-stage company that develops and sells high performance water purification pr...

GlobeNewsWire - 3 months ago

SOUTH ORANGE, NJ, Oct. 16, 2020 (GLOBE NEWSWIRE) -- via NewMediaWire -- Nephros, Inc. (Nasdaq: NEPH) (“Nephros” or the “Company”), a commercial-stage company that develops and sells high perfo...

GlobeNewsWire - 3 months ago

SOUTH ORANGE, NJ, Oct. 13, 2020 (GLOBE NEWSWIRE) -- via NewMediaWire --  Nephros , Inc. (Nasdaq: NEPH), a commercial-stage company that develops and sells high performance water purification p...

GlobeNewsWire - 3 months ago

SOUTH ORANGE, NJ, Oct. 07, 2020 (GLOBE NEWSWIRE) -- via NewMediaWire -- Nephros , Inc. (Nasdaq: NEPH), a commercial-stage company that develops and sells high performance water purification pr...

GlobeNewsWire - 3 months ago

SOUTH ORANGE, NJ, Oct. 06, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Nephros, Inc. (Nasdaq: NEPH), a commercial-stage company that develops and sells high performance water purification prod...

GlobeNewsWire - 5 months ago

  Daron Evans to Remain Senior Science Advisor and CEO of Specialty Renal Products

Seeking Alpha - 5 months ago

Nephros, Inc. (NEPH) CEO Daron Evans on Q2 2020 Results - Earnings Call Transcript

GlobeNewsWire - 5 months ago

SOUTH ORANGE, NJ, Aug. 05, 2020 (GLOBE NEWSWIRE) -- Net Revenue down 32% due to COVID-19 Interruptions

GlobeNewsWire - 5 months ago

SOUTH ORANGE, NJ, July 29, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Nephros, Inc. (Nasdaq: NEPH), a commercial-stage company that develops and sells water purification products and patho...

GlobeNewsWire - 6 months ago

  Nephros SequaPath™, a new microbial screening system, used to evaluate 88 building water samples across four US geographic regions

GlobeNewsWire - 6 months ago

SOUTH ORANGE, N.J., July 13, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Nephros, Inc. (Nasdaq: NEPH ), a commercial-stage company that develops and sells high performance water purifica...

GlobeNewsWire - 6 months ago

Anticipates $1.6 Million Net Revenues

GlobeNewsWire - 7 months ago

SOUTH ORANGE, NJ, June 18, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Nephros, Inc.(Nasdaq:NEPH), a commercial-stage company that develops and sells high performance water purification pro...

GlobeNewsWire - 7 months ago

SOUTH ORANGE, N.J., June 02, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Nephros, Inc. (Nasdaq: NEPH ), a commercial-stage company that develops and sells high performance water purifica...

GlobeNewsWire - 8 months ago

Executives to Present Business Overviews

GlobeNewsWire - 8 months ago

Product Revenue up 43% over Q1 2019

Zacks Investment Research - 9 months ago

Nephros has been struggling lately, but the selling pressure may be coming to an end soon.

GlobeNewsWire - 9 months ago

Anticipates $2.6 Million Net Revenues, Approximately 45% Growth Over 2019

GlobeNewsWire - 9 months ago

Medical Device Veteran Hired to Drive FDA Clearance and Market Launch

GlobeNewsWire - 10 months ago

SOUTH ORANGE, NJ, March 10, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Nephros, Inc.(Nasdaq: NEPH), a commercial stage company that develops and sells high performance water purification p...

Seeking Alpha - 10 months ago

Nephros, Inc. (NEPH) CEO Daron Evans on Q4 2019 Results - Earnings Call Transcript

GlobeNewsWire - 11 months ago

SOUTH ORANGE, NJ, Feb. 20, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Nephros, Inc. (Nasdaq: NEPH), a commercial-stage company that develops and sells high performance water purification p...

GlobeNewsWire - 11 months ago

SOUTH ORANGE, NJ, Jan. 31, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Nephros, Inc. (Nasdaq: NEPH) (“Nephros” or the “Company”), a  commercial-stage company that develops and sells high per...

GlobeNewsWire - 1 year ago

SOUTH ORANGE, NJ, Jan. 09, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Nephros, Inc. (Nasdaq: NEPH), a commercial-stage company that develops and sells high performance water purification p...

GlobeNewsWire - 1 year ago

Anticipates $10.3 Million Full-Year Revenue, Approximately 82% Growth Over 2018; Fourth Quarter Year-Over-Year Revenue Growth Approximately 99%

24/7 Wall Street - 1 year ago

While most of Wall Street focuses on large and mega cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.

Other stocks mentioned: CERS, NOG, SYRS, ZNGA

About NEPH

Nephros, a commercial-stage company, develops and sells liquid purification filters and hemodiafiltration (HDF) systems in the United States. It operates through two segments, Water Filtration and Renal Products. The company's ultrafilters are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, as well as in military and outdoor recreation, commercial, and other healthcare facili... [Read more...]

Industry
Medical Instruments & Supplies
IPO Date
Sep 21, 2004
CEO
Andrew Astor
Employees
25
Stock Exchange
NASDAQ
Ticker Symbol
NEPH
Full Company Profile

Financial Performance

In 2019, Nephros's revenue was $10.33 million, an increase of 81.71% compared to the previous year's $5.69 million. Losses were -$3.42 million, 0.53% more than in 2018.

Financial Statements

Analyst Forecasts

According to 3 analysts, the average rating for Nephros stock is "Buy." The 12-month stock price forecast is 12.92, which is an increase of 65.64% from the latest price.

Price Target
$12.92
(65.64% upside)
Analyst Consensus: Buy